Your browser doesn't support javascript.
loading
Temporal trends and transmission dynamics of pre-treatment HIV-1 drug resistance within and between risk groups in Kenya, 1986-2020.
Nduva, George M; Otieno, Frederick; Kimani, Joshua; Sein, Yiakon; Arimide, Dawit A; Mckinnon, Lyle R; Cholette, Francois; Lawrence, Morris K; Majiwa, Maxwell; Masika, Moses; Mutua, Gaudensia; Anzala, Omu; Graham, Susan M; Gelmon, Larry; Price, Matt A; Smith, Adrian D; Bailey, Robert C; Medstrand, Patrik; Sanders, Eduard J; Esbjörnsson, Joakim; Hassan, Amin S.
Afiliación
  • Nduva GM; Department of Translational Medicine, Lund University, Lund, Sweden.
  • Otieno F; Department of HIV/STI, KEMRI/Wellcome Trust Research Programme, PO Box 230-80108 Kilifi, Kenya.
  • Kimani J; Nyanza Reproductive Health Society, Kisumu, Kenya.
  • Sein Y; Department of Medical Microbiology, University of Nairobi, Nairobi, Kenya.
  • Arimide DA; Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada.
  • Mckinnon LR; Department of HIV/STI, KEMRI/Wellcome Trust Research Programme, PO Box 230-80108 Kilifi, Kenya.
  • Cholette F; Department of Translational Medicine, Lund University, Lund, Sweden.
  • Lawrence MK; Department of Medical Microbiology, University of Nairobi, Nairobi, Kenya.
  • Majiwa M; Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada.
  • Masika M; Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
  • Mutua G; Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada.
  • Anzala O; National Microbiology Laboratory at the JC Wilt Infectious Diseases Research Centre, Public Health Agency of Canada, Winnipeg, Canada.
  • Graham SM; Department of Biochemistry and Biotechnology, Pwani University, Kilifi, Kenya.
  • Gelmon L; Kenya Medical Research Institute/Centre for Global Health Research, Kisumu, Kenya.
  • Price MA; KAVI Institute of Clinical Research, University of Nairobi, Nairobi, Kenya.
  • Smith AD; KAVI Institute of Clinical Research, University of Nairobi, Nairobi, Kenya.
  • Bailey RC; KAVI Institute of Clinical Research, University of Nairobi, Nairobi, Kenya.
  • Medstrand P; Department of HIV/STI, KEMRI/Wellcome Trust Research Programme, PO Box 230-80108 Kilifi, Kenya.
  • Sanders EJ; Department of Medicine, Global Health and Epidemiology, University of Washington, Seattle, USA.
  • Esbjörnsson J; Department of Medical Microbiology, University of Nairobi, Nairobi, Kenya.
  • Hassan AS; Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada.
J Antimicrob Chemother ; 79(2): 287-296, 2024 Feb 01.
Article en En | MEDLINE | ID: mdl-38091580
BACKGROUND: Evidence on the distribution of pre-treatment HIV-1 drug resistance (HIVDR) among risk groups is limited in Africa. We assessed the prevalence, trends and transmission dynamics of pre-treatment HIVDR within and between MSM, people who inject drugs (PWID), female sex workers (FSWs), heterosexuals (HETs) and perinatally infected children in Kenya. METHODS: HIV-1 partial pol sequences from antiretroviral-naive individuals collected from multiple sources between 1986 and 2020 were used. Pre-treatment reverse transcriptase inhibitor (RTI), PI and integrase inhibitor (INSTI) mutations were assessed using the Stanford HIVDR database. Phylogenetic methods were used to determine and date transmission clusters. RESULTS: Of 3567 sequences analysed, 550 (15.4%, 95% CI: 14.2-16.6) had at least one pre-treatment HIVDR mutation, which was most prevalent amongst children (41.3%), followed by PWID (31.0%), MSM (19.9%), FSWs (15.1%) and HETs (13.9%). Overall, pre-treatment HIVDR increased consistently, from 6.9% (before 2005) to 24.2% (2016-20). Among HETs, pre-treatment HIVDR increased from 6.6% (before 2005) to 20.2% (2011-15), but dropped to 6.5% (2016-20). Additionally, 32 clusters with shared pre-treatment HIVDR mutations were identified. The majority of clusters had R0 ≥ 1.0, indicating ongoing transmissions. The largest was a K103N cluster involving 16 MSM sequences sampled between 2010 and 2017, with an estimated time to the most recent common ancestor (tMRCA) of 2005 [95% higher posterior density (HPD), 2000-08], indicating propagation over 12 years. CONCLUSIONS: Compared to HETs, children and key populations had higher levels of pre-treatment HIVDR. Introduction of INSTIs after 2017 may have abrogated the increase in pre-treatment RTI mutations, albeit in the HET population only. Taken together, our findings underscore the need for targeted efforts towards equitable access to ART for children and key populations in Kenya.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Infecciones por VIH / Abuso de Sustancias por Vía Intravenosa / VIH-1 / Seropositividad para VIH / Fármacos Anti-VIH / Trabajadores Sexuales Límite: Child / Female / Humans País/Región como asunto: Africa Idioma: En Revista: J Antimicrob Chemother Año: 2024 Tipo del documento: Article País de afiliación: Suecia

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Infecciones por VIH / Abuso de Sustancias por Vía Intravenosa / VIH-1 / Seropositividad para VIH / Fármacos Anti-VIH / Trabajadores Sexuales Límite: Child / Female / Humans País/Región como asunto: Africa Idioma: En Revista: J Antimicrob Chemother Año: 2024 Tipo del documento: Article País de afiliación: Suecia